Allergan Aesthetics Announces Topline Results From Second Phase 3 Study Of OnabotulinumtoxinA (Botox Cosmetic) For The Treatment Of Platysma Prominence; All Primary And Secondary Endpoints Were Met
–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309).–Results support onabotulinumtoxinA as a potential treatment
